![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PCNX2 |
Gene summary for PCNX2 |
![]() |
Gene information | Species | Human | Gene symbol | PCNX2 | Gene ID | 80003 |
Gene name | pecanex 2 | |
Gene Alias | PCNXL2 | |
Cytomap | 1q42.2 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A6NKB5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80003 | PCNX2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.46e-04 | 4.62e-01 | -0.0811 |
80003 | PCNX2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.50e-03 | 5.12e-01 | -0.059 |
80003 | PCNX2 | HTA11_7663_2000001011 | Human | Colorectum | SER | 5.84e-03 | 4.34e-01 | 0.0131 |
80003 | PCNX2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.79e-02 | 1.91e-01 | 0.0674 |
80003 | PCNX2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 6.20e-07 | 5.98e-01 | 0.0588 |
80003 | PCNX2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.49e-03 | 1.41e-01 | 0.294 |
80003 | PCNX2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.87e-04 | 4.02e-01 | 0.281 |
80003 | PCNX2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.63e-05 | 2.21e-01 | 0.3005 |
80003 | PCNX2 | A002-C-010 | Human | Colorectum | FAP | 1.27e-03 | 3.89e-01 | 0.242 |
80003 | PCNX2 | A001-C-108 | Human | Colorectum | FAP | 1.02e-02 | 3.94e-01 | -0.0272 |
80003 | PCNX2 | A002-C-021 | Human | Colorectum | FAP | 4.72e-16 | 5.28e-01 | 0.1171 |
80003 | PCNX2 | A001-C-104 | Human | Colorectum | FAP | 1.30e-03 | 4.47e-01 | 0.0184 |
80003 | PCNX2 | A015-C-202 | Human | Colorectum | FAP | 4.97e-02 | 3.09e-01 | -0.0849 |
80003 | PCNX2 | A015-C-002 | Human | Colorectum | FAP | 2.96e-02 | 3.98e-01 | -0.0763 |
80003 | PCNX2 | A008-E-015 | Human | Colorectum | FAP | 1.74e-07 | 3.94e-01 | 0.0177 |
80003 | PCNX2 | AEH-subject1 | Human | Endometrium | AEH | 2.66e-23 | 4.00e-01 | -0.3059 |
80003 | PCNX2 | AEH-subject2 | Human | Endometrium | AEH | 1.07e-12 | 3.01e-01 | -0.2525 |
80003 | PCNX2 | AEH-subject3 | Human | Endometrium | AEH | 2.44e-20 | 4.33e-01 | -0.2576 |
80003 | PCNX2 | AEH-subject4 | Human | Endometrium | AEH | 1.17e-16 | 4.06e-01 | -0.2657 |
80003 | PCNX2 | AEH-subject5 | Human | Endometrium | AEH | 1.69e-11 | 2.43e-01 | -0.2953 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PCNX2 | SNV | Missense_Mutation | novel | c.2042N>A | p.Ser681Tyr | p.S681Y | A6NKB5 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-4R-AA8I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PCNX2 | SNV | Missense_Mutation | c.5062G>A | p.Ala1688Thr | p.A1688T | A6NKB5 | protein_coding | deleterious(0) | possibly_damaging(0.886) | TCGA-BC-A112-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
PCNX2 | SNV | Missense_Mutation | c.862G>C | p.Val288Leu | p.V288L | A6NKB5 | protein_coding | tolerated_low_confidence(0.86) | benign(0) | TCGA-DD-A4NS-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PD | |
PCNX2 | SNV | Missense_Mutation | novel | c.3350T>A | p.Val1117Glu | p.V1117E | A6NKB5 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-DD-AAD8-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PCNX2 | SNV | Missense_Mutation | c.819N>G | p.Phe273Leu | p.F273L | A6NKB5 | protein_coding | tolerated_low_confidence(0.15) | benign(0.001) | TCGA-DD-AADI-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PCNX2 | SNV | Missense_Mutation | novel | c.1994A>G | p.Asn665Ser | p.N665S | A6NKB5 | protein_coding | tolerated(0.77) | benign(0.003) | TCGA-DD-AADS-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PCNX2 | SNV | Missense_Mutation | novel | c.3747N>A | p.Ser1249Arg | p.S1249R | A6NKB5 | protein_coding | tolerated(0.35) | benign(0.212) | TCGA-DD-AAVU-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
PCNX2 | SNV | Missense_Mutation | c.365A>G | p.Asn122Ser | p.N122S | A6NKB5 | protein_coding | tolerated(0.33) | benign(0.098) | TCGA-G3-A25S-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sunitinib | PD | |
PCNX2 | SNV | Missense_Mutation | c.2984N>T | p.Gly995Val | p.G995V | A6NKB5 | protein_coding | deleterious(0.01) | probably_damaging(0.959) | TCGA-G3-A3CJ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD | |
PCNX2 | SNV | Missense_Mutation | c.2643N>T | p.Gln881His | p.Q881H | A6NKB5 | protein_coding | tolerated(0.07) | benign(0.376) | TCGA-UB-A7MB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |